← Leaderboards
Babal K Jha
Cleveland Clinic Lerner Com-Cwru
$2,797,884
Attributed
$5,595,767
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,595,767 · 2
By mechanism
R01$5,595,767 · 2
Top collaborators
- Jaroslaw P Maciejewski9 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Jaroslaw P Maciejewski$28,244,801
- Serpil C. Erzurum$45,061,611
- Jay L Alberts$15,319,411
- Ruth A Keri$12,224,731
- Srinivasan Dasarathy$21,059,442
Others in their field
Other Emerging Leaders on “Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,728,591
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,752,686
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,170,219
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$10,343,043
Research focus
LeukemiaIn Vivo ModelEnzymesHematopoietic Stem CellsIn VitroIn VivoCell LineageEnhancersEpigenetic ProcessHematopoieticAlpha KetoglutarateBiochemicalBiologicalDioxygenasesAffectCell LineCellsElderlyAscorbic AcidDemethylationGenesHematopoiesisCd34 GeneLoss Of Function Mutation
Grant awards (9)
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2025 · DK
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$608,324
R01 · FY2025 · CA
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$632,461
R01 · FY2024 · DK
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$577,908
R01 · FY2024 · CA
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2023 · DK
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$596,157
R01 · FY2023 · CA
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells$658,812
R01 · FY2022 · DK
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$596,157
R01 · FY2022 · CA
Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms$608,324
R01 · FY2021 · CA